Shionogi
SGIOYDrugs in Pipeline
41
Phase 3 Programs
21
Upcoming Catalysts
3
Next Catalyst
Dec 2026
Market Overview
Stock performance and key metrics
3 upcoming, 1 past
Ospemifene (Dose 1)
Atrophy
CLONICEL (Clonidine HCl sustained release)
Attention Deficit Hyperactivity Disorder
Ospemifene 30 mg
Atrophy
Cefiderocol
Urinary Tract Infections
S-268019-b
SARS-CoV-2
Ospemifene
Vaginal Dryness
Pravafen
Combined Hyperlipidemia
Oral Glycopyrrolate Liquid
Cerebral Palsy
Meropenem
Healthcare-associated Pneumonia (HCAP)
Lusutrombopag
Chronic Liver Disease
Best Available Therapy
Healthcare-associated Pneumonia (HCAP)
Naldemedine
Opioid-induced Constipation
Ospemifene 60Mg Oral Tablet
Atrophy
S-217622
SARS-CoV-2 Infection
Duloxetine Hydrochloride
Depressive Disorder
Oseltamivir
Influenza
Baloxavir Marboxil
Influenza
MCI-186
Acute Ischemic Stroke (AIS)
MT-1186
Amyotrophic Lateral Sclerosis (ALS)
MCI-186 in open label phase
Amyotrophic Lateral Sclerosis (ALS)
Ospemifene 60 mg
Atrophy
S-2367 800 mg
Obesity
S-606001
Pompe Disease
S-555739 Dose 1
Seasonal Allergic Rhinitis
S-309309
Obesity
S-892216
COVID-19
S-777469 400 mg
Atopic Dermatitis
S-337395
Respiratory Syncytial Virus Infections
S-531011
Solid Tumors
Standard of Care
Gram-negative Bacterial Infections
S-2367 1600 mg q.d. 54 Weeks
Obesity
Redasemtide
Acute Ischemic Stroke
S-707106 Dose A
Type 2 Diabetes Mellitus
Sivopixant
Sleep Apnea
50 mg S-777469
Atopic Dermatitis
Ospemifene 5 mg
Atrophy
S-3304
Non Small Cell Lung Cancer
Velneperit 400 mg
Obesity
S-600918
Chronic Cough
S-2367 (velneperit)
Obesity
BPN14770
Jordan's Syndrome
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Ospemifene (Dose 1) | Phase 3 | Atrophy | - | - |
CLONICEL (Clonidine HCl sustained release) | Phase 3 | Attention Deficit Hyperactivity Disorder | - | - |
Ospemifene 30 mg | Phase 3 | Atrophy | - | - |
Cefiderocol | Phase 3 | Urinary Tract Infections | - | - |
S-268019-b | Phase 3 | SARS-CoV-2 | - | - |
Ospemifene | Phase 3 | Vaginal Dryness | - | - |
Pravafen | Phase 3 | Combined Hyperlipidemia | - | - |
Oral Glycopyrrolate Liquid | Phase 3 | Cerebral Palsy | - | - |
Meropenem | Phase 3 | Healthcare-associated Pneumonia (HCAP) | - | - |
Lusutrombopag | Phase 3 | Chronic Liver Disease | - | - |
Best Available Therapy | Phase 3 | Healthcare-associated Pneumonia (HCAP) | - | - |
Naldemedine | Phase 3 | Opioid-induced Constipation | - | - |
Ospemifene 60Mg Oral Tablet | Phase 3 | Atrophy | - | - |
S-217622 | Phase 3 | SARS-CoV-2 Infection | - | - |
Duloxetine Hydrochloride | Phase 3 | Depressive Disorder | - | - |
Oseltamivir | Phase 3 | Influenza | - | - |
Baloxavir Marboxil | Phase 3 | Influenza | - | - |
MCI-186 | Phase 3 | Acute Ischemic Stroke (AIS) | - | - |
MT-1186 | Phase 3 | Amyotrophic Lateral Sclerosis (ALS) | - | - |
MCI-186 in open label phase | Phase 3 | Amyotrophic Lateral Sclerosis (ALS) | - | - |
Ospemifene 60 mg | Phase 3 | Atrophy | - | - |
S-2367 800 mg | Phase 2 | Obesity | - | - |
S-606001 | Phase 2 | Pompe Disease | - | - |
S-555739 Dose 1 | Phase 2 | Seasonal Allergic Rhinitis | - | - |
S-309309 | Phase 2 | Obesity | - | - |
S-892216 | Phase 2 | COVID-19 | - | - |
S-777469 400 mg | Phase 2 | Atopic Dermatitis | - | - |
S-337395 | Phase 2 | Respiratory Syncytial Virus Infections | - | - |
S-531011 | Phase 2 | Solid Tumors | - | - |
Standard of Care | Phase 2 | Gram-negative Bacterial Infections | - | - |
S-2367 1600 mg q.d. 54 Weeks | Phase 2 | Obesity | - | - |
Redasemtide | Phase 2 | Acute Ischemic Stroke | - | - |
S-707106 Dose A | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Sivopixant | Phase 2 | Sleep Apnea | - | - |
50 mg S-777469 | Phase 2 | Atopic Dermatitis | - | - |
Ospemifene 5 mg | Phase 2 | Atrophy | - | - |
S-3304 | Phase 2 | Non Small Cell Lung Cancer | - | - |
Velneperit 400 mg | Phase 2 | Obesity | - | - |
S-600918 | Phase 2 | Chronic Cough | - | - |
S-2367 (velneperit) | Phase 2 | Obesity | - | - |
BPN14770 | Phase 2 | Jordan's Syndrome | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Shionogi's drug pipeline?→
CatalystAlert tracks 41 drug candidates in Shionogi's (SGIOY) pipeline across Phase 3, Phase 2. Its lead program is Ospemifene (Dose 1) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Shionogi's next FDA catalyst?→
Shionogi's (SGIOY) next tracked catalyst is a Phase 2 expected December 30, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SGIOY biotech catalysts?→
Add SGIOY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Shionogi's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.